Toll Free: 1-888-928-9744

AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Published: May 31, 2016 | Pages: 62 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by AVEO Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of AVEO Pharmaceuticals, Inc.
- The report provides overview of AVEO Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses AVEO Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features AVEO Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate AVEO Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for AVEO Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AVEO Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 AVEO Pharmaceuticals, Inc. Snapshot 6 AVEO Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 AVEO Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 AVEO Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 AVEO Pharmaceuticals, Inc. - Pipeline Products Glance 16 AVEO Pharmaceuticals, Inc. - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 AVEO Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 AVEO Pharmaceuticals, Inc. - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 AVEO Pharmaceuticals, Inc. - Drug Profiles 21 tivozanib hydrochloride 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ficlatuzumab 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AV-203 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AV-232 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AV-353 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GP-369 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 AV-370 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Monoclonal Antibody to Antagonize FGFR1 for Cancer 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Monoclonal Antibody to Antagonize FGFR4 for Cancer 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody to Target Notch2 for Cancer 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody to Target Notch3 for Cancer 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Monoclonal Antibody to Target Notch4 for Cancer 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 AVEO Pharmaceuticals, Inc. - Pipeline Analysis 39 AVEO Pharmaceuticals, Inc. - Pipeline Products by Target 39 AVEO Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 41 AVEO Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 42 AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 43 AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates 45 AVEO Pharmaceuticals, Inc. - Dormant Projects 54 AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products 55 Discontinued Pipeline Product Profiles 55 AV-412 55 tivozanib hydrochloride 55 AVEO Pharmaceuticals, Inc. - Company Statement 56 AVEO Pharmaceuticals, Inc. - Locations And Subsidiaries 60 Head Office 60 Other Locations & Subsidiaries 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
AVEO Pharmaceuticals, Inc., Key Information 6 AVEO Pharmaceuticals, Inc., Key Facts 6 AVEO Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8 AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12 AVEO Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13 AVEO Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 14 AVEO Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15 AVEO Pharmaceuticals, Inc. - Phase III, 2016 16 AVEO Pharmaceuticals, Inc. - Phase II, 2016 17 AVEO Pharmaceuticals, Inc. - Phase I, 2016 18 AVEO Pharmaceuticals, Inc. - Preclinical, 2016 19 AVEO Pharmaceuticals, Inc. - Discovery, 2016 20 AVEO Pharmaceuticals, Inc. - Pipeline by Target, 2016 39 AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 41 AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 42 AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 44 AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 45 AVEO Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 54 AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 55 AVEO Pharmaceuticals, Inc., Subsidiaries 60


List of Figures
AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 8 AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12 AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 39 AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 41 AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 42 AVEO Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 43

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify